BUPIVACAINE HYDROCHLORIDE

Search structure
Trade Names:
Synonyms:
Status: Approved (1972)
Entry Type: Small molecule
Molecule Category: Salt
UNII: AKA908P8J1
Parent Compound: BUPIVACAINE

Structure
InChI Key SIEYLFHKZGLBNX-UHFFFAOYSA-N
Smile CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C.Cl
InChI
InChI=1S/C18H28N2O.ClH/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3;/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21);1H

Physicochemical Descriptors

Property Name Value
Molecular Formula C18H29ClN2O
Molecular Weight 324.9
AlogP 3.9
Hydrogen Bond Acceptor 2.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 5.0
Polar Surface Area 32.34
Molecular species NEUTRAL
Aromatic Rings 1.0
Heavy Atoms 21.0

Pharmacology

Action Mechanism of Action Reference
BLOCKER Sodium channel protein type IV alpha subunit blocker PubMed
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Ion channel Voltage-gated ion channel Potassium channels Voltage-gated potassium channel
- 22000-95000 - - -
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - 94

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Cleft Palate 3 D002972 ClinicalTrials
Osteoarthritis 3 D010003 ClinicalTrials
Hallux Valgus 3 D006215 ClinicalTrials
Radiculopathy 3 D011843 ClinicalTrials
Peritoneal Neoplasms 3 D010534 ClinicalTrials
Hemorrhoids 3 D006484 ClinicalTrials
Hernia, Inguinal 2 D006552 ClinicalTrials
Wounds and Injuries 2 D014947 ClinicalTrials
Neoplasms 2 D009369 ClinicalTrials
HIV Infections 1 D015658 ClinicalTrials
Hot Flashes 0 D019584 ClinicalTrials

Related Entries

Scaffolds

Parent
Mixture
Mixture
Mixture

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
24.4
Injury, poisoning and procedural complications
14.71
Nervous system disorders
12.69
Musculoskeletal and connective tissue disorders
6.73
Cardiac disorders
6.26
Vascular disorders
4.86
Infections and infestations
4.75
Skin and subcutaneous tissue disorders
3.78
Product issues
2.82
Respiratory, thoracic and mediastinal disorders
2.6
Pregnancy, puerperium and perinatal conditions
2.5
Investigations
2.37
Immune system disorders
2.02

Cross References

Resources Reference
ChEBI 77441
ChEMBL CHEMBL1200396
EPA CompTox DTXSID0030877
FDA SRS AKA908P8J1
PubChem 5282419
SureChEMBL SCHEMBL34374
ZINC ZINC01530814
CONTENTS